Scientific conclusions and grounds for the variation to the 
terms of the marketing authorisation(s) 
Active substance(s): clofarabine 
Procedure No. EMEA/H/C/PSUSA/00000805/201912 
23 July 2020 
EMA/517911/2020 
Committee for Medicinal Products for Human Use (CHMP) 
Medicinal product no longer authorised
Period covered by the PSUR: 14 November 2019 – 28 December 2019 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scientific conclusions 
Taking into account the PRAC Assessment Report on the PSUR(s) for clofarabine, the scientific 
conclusions of CHMP are as follows:  
changes to the product information 
updated to explicit the need of filtration.  
The CHMP agrees with the scientific conclusions made by the PRAC. 
Grounds for the variation to the terms of the marketing authorisation(s) 
The CHMP recommends that the terms of the marketing authorisation(s) should be varied. 
balance of the medicinal product(s) containing clofarabine is unchanged subject to the proposed 
On the basis of the scientific conclusions for clofarabine the CHMP is of the opinion that the benefit-risk 
Several  cases  reporting  non-filtration  of  Evoltra  were  identified  during  the  reporting  period.  No  safety 
signal emerged from these cases, however regarding the theoretical risk of presence of particles that may 
lead to adverse reactions or product neutralisation when filtration is omitted, and the fact that some cases 
of omission of filtration during drug preparation have also been reported in the European Union during 
the review period, the PRAC is of opinion that the product information of clofarabine products should be 
Medicinal product no longer authorised
Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)  
EMA/517911/2020 
Page 2/2 
  
  
 
 
 
 
 
 
